Acute stress increases circulating anandamide and other n-acylethanolamines in healthy humans

Neuropsychopharmacology

Volumn 37, Issue 11, 2012, Pages 2416-2427

  Dlugos, Andrea ^a,b   Childs, Emma ^b   Stuhr, Kara L ^c   Hillard, Cecilia J ^c   De Wit, Harriet ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

2 arachidonoylglycerol; anxiety; cortisol; endocannabinoid; N arachidonylethanolamine; stress

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; HYDROCORTISONE; N OLEOYLETHANOLAMINE; PALMIDROL;

ACUTE STRESS; ADULT; AFRICAN AMERICAN; ANXIETY; ARTICLE; ASIAN; BLOOD LEVEL; BLOOD SAMPLING; CIRCULATION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDIATOR; MENSTRUAL CYCLE; NORMAL HUMAN; PRIORITY JOURNAL; SEX; STRESS; VOLUNTEER;

ACUTE DISEASE; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CROSS-SECTIONAL STUDIES; ETHANOLAMINES; FEMALE; HEART RATE; HUMANS; HYDROCORTISONE; LIPIDS; MALE; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; STRESS, PSYCHOLOGICAL; TIME FACTORS; YOUNG ADULT;

EID: 84866378334     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.100     Document Type: Article

References (64)

1. Ahwal WN, Mills PJ, Kalshan DA, Nelesen RA (1997). Effects of race and sex on blood pressure and hemodynamic stress response as a function of the menstrual cycle. Blood Press Monit 2: 161-167. (Pubitemid 27464340)
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press: Washington, DC.
3. Asnaani A, Richey JA, Dimaite R, Hinton DE, Hofmann SG (2010). A cross-ethnic comparison of lifetime prevalence rates of anxiety disorders. J Nerv Ment Dis 198: 551-555.
4. Bambico FR, Katz N, Debonnel G, Gobbi G (2007). Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27: 11700-11711. (Pubitemid 350006914)
5. Childs E, de Wit H (2010). Effects of acute psychosocial stress on cigarette craving and smoking. Nicotine Tob Res 12: 449-453.
6. Childs E, Dlugos A, De Wit H (2010). Cardiovascular, hormonal, and emotional responses to the TSST in relation to sex and menstrual cycle phase. Psychophysiology 47: 550-559.
7. Chong RY, Uhart M, McCaul ME, Johnson E, Wand GS (2008). Whites have a more robust hypothalamic-pituitary-adrenal axis response to a psychological stressor than blacks. Psychoneuroendocrinology 33: 246-254.
8. Chouker A, Kaufmann I, Kreth S, Hauer D, Feuerecker M, Thieme D et al (2010). Motion sickness, stress and the endocannabinoid system. PLoS One 5: e10752.
9. Chrousos GP, Kino T, Charmandari E (2009). Evaluation of the hypothalamic-pituitary-adrenal axis function in childhood and adolescence. Neuroimmunomodulation 16: 272-283.
10. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP et al (2007). Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31: 692-699. (Pubitemid 46482358)
11. Dannlowski U, Stuhrmann A, Beutelmann V, Zwanzger P, Lenzen T, Grotegerd G et al (2012). Limbic scars: long-term consequences of childhood maltreatment revealed by functional and structural magnetic resonance imaging. Biol Psychiatry 71: 286-293.
12. Derogatis L (1983). SCL-90-R Manual II. Clinical Psychometric Research: Towson,
13. MD. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA et al (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264: 258-267. (Pubitemid 29385890)
14. Di Marzo V, De Petrocellis L, Bisogno T (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol 168: 147-185.
15. Di Marzo V, Ligresti A, Cristino L (2009). The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes (Lond) 33(Suppl 2): S18-S24.
16. Esler M, Eikelis N, Schlaich M, Lambert G, Alvarenga M, Kaye D et al (2008). Human sympathetic nerve biology: parallel influences of stress and epigenetics in essential hypertension and panic disorder. Ann NY Acad Sci 1148: 338-348.
17. Fraser GA (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 15: 84-88.
18. Gaetani S, Sipasquale P, Romano A, Righetti L, Cassano T, Piomelli D et al (2009). The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurolbiol 85: 57-72.
19. Glaser ST, Gatley SJ, Gifford AN (2006). Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain. J Pharmacol Exp Ther 316: 1088-1097. (Pubitemid 43345282)
20. Gorzalka BB, Hill MN, Hillard CJ (2008). Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 32: 1152-1160.
21. Habayeb OM, Taylor AH, Evans MD, Cooke MS, Taylor DJ, Bell SC et al (2004). Plasma levels of the endocannabinoid anandamide in women-a potential role in pregnancy maintenance and labor? J Clin Endocrinol Metab 89: 5482-5487. (Pubitemid 39518429)
22. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G (2009c). The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 30: 484-493.
23. Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ et al (2009b). Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 34: 2733-2745.
24. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009a). Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34: 1257-1262.
25. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ (2008). Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41: 48-53. (Pubitemid 351427522)
26. Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS (2010). Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 30: 14980-14986.
27. Hillard CJ, Weinlander KM, Stuhr KL (2012). Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 204: 207-299.
28. Ho WS, Hillard CJ (2005). Modulators of endocannabinoid enzymic hydrolysis and membrane transport. Handb Exp Pharmacol 168: 187-207.
29. Johanson CE, Uhlenhuth EH (1980). Drug preference and mood in humans: diazepam. Psychopharmacology (Berl) 71: 269-273. (Pubitemid 11194003)
30. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380.
31. Kirschbaum C, Kudielka BM, Gaab J, Schommer NC, Hellhammer DH (1999). Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitaryadrenal axis. Psychosom Med 61: 154-162. (Pubitemid 29168644)
32. Kirschbaum C, Pirke KM, Hellhammer DH (1993a). The 'Trier Social Stress Test'-a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 76-81. (Pubitemid 23283755)
33. Kirschbaum C, Strasburger CJ, Langkrar J (1993b). Attenuated cortisol response to psychological stress but not to CRH or ergometry in young habitual smokers. Pharmacol Biochem Behav 44: 527-531.
34. Krishnan V, Nestler EJ (2008). The molecular neurobiology of depression. Nature 455: 894-902.
35. Kunos G, Jarai Z, Batkai S, Goparaju SK, Ishac EJ, Liu J et al (2000). Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 108: 159-168.
36. Lepore SJ, Allen KA, Evans GW (1993). Social support lowers cardiovascular reactivity to an acute stressor. Psychosom Med 55: 518-524. (Pubitemid 23354462)
37. Lopez JF, Akil H, Watson SJ (1999). Neural circuits mediating stress. Biol Psychiatry 46: 1461-1471.
38. Matthews KA, Gump BB, Owens JF (2001). Chronic stress influences cardiovascular and neuroendocrine responses during acute stress and recovery, especially in men. Health Psychol 20: 403-410. (Pubitemid 33032792)
39. McCarron RM, Chen Y, Tomori T, Strasser A, Mechoulam R, Shohami E et al (2006). Endothelial-mediated regulation of cerebral microcirculation. J Physiol Pharmacol 57(Suppl 11): 133-144. (Pubitemid 46569839)
40. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F et al (2009). Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34: 593-606.
41. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH (2007). Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192: 61-70. (Pubitemid 46673891)
42. O'Sullivan SE, Kendall DA (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215: 611-616.
43. Parker KJ, Schatzberg AF, Lyons DM (2003). Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav 43: 60-66. (Pubitemid 36293275)
44. Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS et al (2005b). The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res 46: 342-349. (Pubitemid 40271098)
45. Patel S, Cravatt BF, Hillard CJ (2005a). Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 30: 497-507. (Pubitemid 40271152)
46. Patel S, Hillard CJ (2008). Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. Eur J Neurosci 27: 2821-2829. (Pubitemid 351832221)
47. Patel S, Hillard CJ (2009). Endocannabinoids as modulators of synaptic signaling. In: Reggio PH (ed). The Cannabinoid Receptors. Humana Press: New York, pp 281-308.
48. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004). Endocannabinoid signaling negatively modulates stressinduced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145: 5431-5438. (Pubitemid 39564580)
49. Rademacher DJ, Meier SE, Shi L, Ho WS, Jarrahian A, Hillard CJ (2008). Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 54: 108-116. (Pubitemid 350299407)
50. Randall MD, Kendall DA, Bennett AJ, O'Sullivan SE (2007). Rimonabant in obese patients with type 2 diabetes. Lancet 369: 555. (Pubitemid 46241434)
51. Schroeder C, Batkai S, Engeli S, Tank J, Diedrich A, Luft FC et al (2009). Circulating endocannabinoid concentrations during orthostatic stress. Clin Auton Res 19: 343-346.
52. Selzer ML (1971). The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 127: 1653-1658.
53. Sherwood A, May CW, Siegel WC, Blumenthal JA (1995). Ethnic differences in hemodynamic responses to stress in hypertensive men and women. Am J Hypertens 8: 552-557.
54. Sinha R (2008). Chronic stress, drug use, and vulnerability to addiction. Ann NY Acad Sci 1141: 105-130.
55. Stella N, Schweitzer P, Piomelli D (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773-778. (Pubitemid 27375156)
56. Sugiura T, Kishimoto S, Oka S, Gokoh M (2006). Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45: 405-446.
57. Taylor AH, Amoako AA, Bambang K, Karasu T, Gebeh A, Lam PM et al (2010). Endocannabinoids and pregnancy. Clin Chim Acta 411: 921-930.
58. Tsuboi K, Takezaki N, Ueda N (2007). The N-acylethanolaminehydrolyzing acid amidase (NAAA). Chem Biodivers 4: 1914-1925.
59. Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T (1995). Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 270: 23823-23827.
60. Ueda N, Tsuboi K, Uyama T (2010). Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801: 1274-1285.
61. Uriguen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J (2004). Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966-973. (Pubitemid 38471950)
62. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390: 518-521. (Pubitemid 28013133)
63. Willoughby KA, Moore SF, Martin BR, Ellis EF (1997). The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282: 243-247. (Pubitemid 27425547)
64. Wood JT, Williams JS, Pandarinathan L, Courville A, Keplinger MR, Janero DR et al (2008). Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin Chem Lab Med 46: 1289-1295.